Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

Investing.com-- Bank of America (BofA) analysts highlighted several Japanese stocks as top picks following strong ...

We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

SBI Q3 Results LIVE: Capital Adequacy Ratio (CAR) as at the end of Q3FY25 stands at 13.03%, shows an exchange filing. - Credit growth at 13.49% YoY with domestic advances growing by 14.06% YoY.

Ralph Lauren posts Q3 sales growth of 11% to $2.14 billion. Ralph Lauren now expects FY25 revenues to increase 6% - 7% in CC. Get access to your new suite of high-powered trading tools ...

However, the company’s total premium surged 37 per cent to ₹1,151 crore in Q3FY25 of this fiscal against ₹841 crore in Q3 of FY24, driven by group premium which more than doubled year-on ...

Follow our LIVE blog for the latest updates. We wrap up today's edition of the Moneycontrol live Q3 earnings blog, and will be back tomorrow morning with all the latest updates and alerts.

ARM stock is in a strong bullish trend, trading above key moving averages ahead of Q3 earnings. Analysts maintain a bullish rating but see a 7% downside from current levels based on price targets.

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind everyone that we ...

Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 ...